Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21663156 | 0.84 | KDM4E (0.33) | KDM4EMEN1KMT2A | |
| SCHEMBL21662993 | 0.84 | PDE5A (0.34) | KDM4EMEN1KMT2A | |
| SCHEMBL21663151 | 0.77 | CYP1A2 (0.36) | CYP1A2CYP3A4CYP2C19KDM4EMEN1 | |
| SCHEMBL21663311 | 0.77 | KDM4E (0.34) | KDM4EMEN1KMT2ASMARCA4 | |
| SCHEMBL21663142 | 0.71 | KDM4E (0.32) | KDM4EMEN1KMT2A | |
| SCHEMBL21663307 | 0.68 | KDM4E (0.33) | KDM4EMEN1KMT2A | |
| SCHEMBL21663300 | 0.66 | ADORA2A (0.38) | CYP2C19KDM4EMEN1KMT2A | |
| SCHEMBL21663205 | 0.65 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2C19KDM4E | |
| SCHEMBL21663173 | 0.65 | KDM4E (0.31) | KDM4EMEN1KMT2A | |
| SCHEMBL21663040 | 0.63 | KDM4E (0.32) | KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168088-B2 | Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. | 2021-11-09 | — | — | US | disclosed |
| US-20200039983-A1 | PYRIDYLAMINO SUBSTITUTED HETEROTRICYCLIC COMPOUNDS, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168088-B2 | Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof | CYP2D6, PNPO, CYP2B6 | CYP1A2 39/4885CYP3A4 48/4885CYP2C19 12/4885 |
| US-20200039983-A1 | PYRIDYLAMINO SUBSTITUTED HETEROTRICYCLIC COMPOUNDS, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | CYP2D6, PNPO, CYP2B6 | CYP1A2 39/4885CYP3A4 48/4885CYP2C19 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.